US Tariff Uncertainty
The US has initiated a Section 232 investigation into pharmaceutical imports, which could lead to tariffs. Management has a directional plan but no clarity on outcome.
high · analyst_questionAjanta Pharma Limited — Q4 FY25
Ajanta Pharma delivered a solid Q4 FY25 with consolidated revenue of INR 1,170 crore (+11% YoY) and PAT of INR 225 crore (+11% YoY).
bullish
high
Financial stats pending filing verification
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Africa Institutional Business Volatility
The Africa institutional segment declined 53% in Q4 and remains unpredictable due to donor funding uncertainties, including potential USAID cuts.
medium · management_commentaryElevated Personnel Costs Impacting Margins
Personnel costs rose 21% in FY25 due to MR additions and gratuity policy changes, pressuring EBITDA margins. Normalization expected in FY26 but full-year impact remains.
medium · data_observationOphthalmology Segment Slowdown
Ophthalmology grew only 5% in FY25, below company average. Management attributed it to market trends but offered no specific mitigation plan.
low · analyst_question